Battle of the bacteria: which drug combo wins against resistant h. pylori?
NCT ID NCT03431688
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study tested two different drug combinations in 782 people with H. pylori infection that was resistant to the antibiotic clarithromycin. One group received a triple therapy with a proton pump inhibitor, amoxicillin, and metronidazole, while the other received a quadruple therapy with a proton pump inhibitor, bismuth, metronidazole, and tetracycline. The goal was to see which combination better eradicated the bacteria.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
metronidazole-based triple therapy (PPI, amoxicillin, metronidazole) and bismuth-based quadruple therapy (PPI, bismuth, metronidazole, tetracycline)
What this could lead to
If successful, this could identify a more effective treatment for people with drug-resistant H. pylori, reducing infection and related complications.
What could go wrong
This is a completed trial, but results may not apply to all populations. Drug resistance patterns vary, and side effects from the medications can occur.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HELICOBACTER PYLORI INFECTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Kangdong Sacred Heart Hospital
Seoul, 134-701, South Korea